Blueprint Medicines (NASDAQ:BPMC) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday, September 17th.
Other equities research analysts have also issued research reports about the company. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, August 1st. JMP Securities lowered their price objective on Blueprint Medicines from $109.00 to $103.00 and set a “buy” rating on the stock in a report on Monday, June 4th. Zacks Investment Research raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. Finally, BidaskClub raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $93.11.
Shares of NASDAQ BPMC traded up $1.93 during midday trading on Monday, reaching $69.11. 275,972 shares of the company were exchanged, compared to its average volume of 402,144. The company has a quick ratio of 12.36, a current ratio of 12.36 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a 1 year low of $57.44 and a 1 year high of $109.00. The firm has a market cap of $3.43 billion, a P/E ratio of -17.63 and a beta of 1.08.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.32) by $0.70. Blueprint Medicines had a negative return on equity of 32.61% and a negative net margin of 326.99%. The company had revenue of $41.40 million for the quarter, compared to analyst estimates of $2.62 million. During the same quarter in the previous year, the company earned ($0.86) EPS. The firm’s revenue for the quarter was up 602.9% compared to the same quarter last year. As a group, analysts anticipate that Blueprint Medicines will post -5.15 earnings per share for the current year.
In related news, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $70.59, for a total transaction of $1,411,800.00. Following the completion of the transaction, the chief executive officer now directly owns 20,000 shares in the company, valued at approximately $1,411,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Marion Dorsch sold 2,300 shares of Blueprint Medicines stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $70.47, for a total value of $162,081.00. Following the transaction, the insider now owns 2,300 shares of the company’s stock, valued at $162,081. The disclosure for this sale can be found here. Insiders own 3.15% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. NumerixS Investment Technologies Inc raised its holdings in Blueprint Medicines by 750.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,100 shares of the biotechnology company’s stock valued at $311,000 after acquiring an additional 4,500 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Blueprint Medicines by 7.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 25,236 shares of the biotechnology company’s stock valued at $1,602,000 after buying an additional 1,740 shares during the period. grace capital purchased a new stake in shares of Blueprint Medicines during the 2nd quarter valued at $171,000. Swiss National Bank grew its stake in shares of Blueprint Medicines by 3.9% during the 1st quarter. Swiss National Bank now owns 67,200 shares of the biotechnology company’s stock valued at $6,162,000 after buying an additional 2,500 shares during the period. Finally, Bollard Group LLC grew its stake in shares of Blueprint Medicines by 38.6% during the 2nd quarter. Bollard Group LLC now owns 53,000 shares of the biotechnology company’s stock valued at $3,364,000 after buying an additional 14,750 shares during the period. Institutional investors own 99.76% of the company’s stock.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: Hedge Funds – How They Work For Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.